Anthraquinone derivative O,O′-bis-(3′-iodopropyl)-1,4- dihidroxyanthraquinone modulates immune response and improves experimental autoimmune encephalomyelitis

International Immunopharmacology

Volumn 14, Issue 2, 2012, Pages 127-132

  Alves, Caio C S ^a   Castro, Sandra B R ^a   Costa, Cristiane F ^a   Dias, Alyria T ^a   Alves, Chrystian J ^a   Rodrigues, Michele F ^a   Teixeira, Henrique C ^a   Almeida, Mauro V ^a   Ferreira, Ana Paula ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Chemokines; Cytokines; EAE; Mitoxantrone analog; Multiple sclerosis

Indexed keywords

ANTHRAQUINONE DERIVATIVE; GAMMA INTERFERON; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MITOXANTRONE; MYELIN PROTEIN; O,O' BIS (3' IODOPROPYL) 1,4 DIHIDROXYANTHRAQUINONE; RANTES; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOTOXICITY; DEMYELINATION; DRUG EFFECT; FEMALE; HISTOLOGY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATORY CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SPINAL CORD;

ANIMALS; CELL LINE; CELL MOVEMENT; CELL SURVIVAL; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNITY; IMMUNOMODULATION; INFLAMMATION MEDIATORS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MITOXANTRONE; MULTIPLE SCLEROSIS; SPINAL CORD;

EID: 84864055206     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.06.013     Document Type: Article

References (32)

1. M. Pugliatti, S. Sotgiu, and G. Rosati The worldwide prevalence of multiple sclerosis Clin Neurol Neurosurg 104 2002 182 191 (Pubitemid 34792722)
2. A. Compston, and A. Coles Multiple sclerosis Lancet 359 2002 1221 1231 (Pubitemid 34304266)
3. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
4. C.J. Hedegaard, M. Krakauer, K. Bendtzen, H. Lund, F. Sellebjerg, and C.H. Nielsen T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis Immunology 125 2008 161 169
5. V.K. Kuchroo, A.C. Anderson, H. Waldner, M. Munder, E. Bettelli, and L.B. Nicholson T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire Annu Rev Immunol 20 2002 101 123 (Pubitemid 34293422)
6. B.S. Wang, A.L. Lumanglas, J. Silva, V.M. Ruszala-Mallon, and F.E. Durr Inhibition of the induction of alloreactivity with mitoxantrone Int J Immunopharmacol 8 1986 967 973 (Pubitemid 17205416)
7. S.L. Galetta, and C. Markowitz US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles CNS Drugs 19 2005 239 252 (Pubitemid 40460663)
8. J.J. Marriott, J.M. Miyasaki, G. Gronseth, and P.W. O'Connor Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology Neurology 74 2010 1463 1470
9. M. Teixeira, F. Cerqueira, C.M. Barbosa, M.S. Nascimento, and M. Pinto Improvement of the inhibitory effect of xanthones on NO production by encapsulation in PLGA nanocapsules J Drug Target 13 2005 129 135 (Pubitemid 40542545)
10. T.A. Corrêa, E.F.C. Reis, L.L. Alves, C.C.S. Alves, S.B.R. Castro, and A.T. Dias Preparation of amino alcohols condensed with carbohydrates: evaluation of cytotoxicity and inhibitory effect on NO production Chem Biol Drug Des 76 2010 451 456
11. W.H. Piao, R. Wong, X.F. Bai, J. Huang, D.I. Campagnolo, and R.T. Dorr Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis J Immunol 179 2007 7415 7423
12. M.L. De Paula, D.H. Rodrigues, H.C. Teixeira, M.M. Barsante, M.A. Souza, and A.P. Ferreira Genistein down-modulates pro-inflammatory cytokines and reverses clinical signs of experimental autoimmune encephalomyelitis Int Immunopharmacol 8 2008 1291 1297
13. S.B.R. Castro, C.O.R. Junior, C.C.S. Alves, A.T. Dias, L.L. Alves, and L. Mazzoccoli Immunomodulatory effects and improved prognosis of experimental autoimmune encephalomyelitis after O-tetradecanoyl-genistein treatment Int Immunopharmacol 12 2012 465 470
14. E.J. Fox Management of worsening multiple sclerosis with mitoxantrone: a review Clin Ther 28 2006 461 474 (Pubitemid 44208782)
15. O. Neuhaus, B.C. Kieseier, and H.P. Hartung Therapeutic role of mitoxantrone in multiple sclerosis Pharmacol Ther 109 2006 198 209 (Pubitemid 41740821)
16. B. Drewinko, L.Y. Yang, B. Barlogie, and J.M. Trujillo Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthra-cenedione diacetate, and doxorubicin on human cells in vitro Cancer Res 43 1983 2648 2653 (Pubitemid 13100525)
17. J. Kapuscinski, and Z. Darzynkiewicz Relationship between the pharmacological activity of antitumor drugs ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids Proc Natl Acad Sci U S A 83 1986 6302 6306 (Pubitemid 17174724)
18. J.O. Morley, and P.J. Furlong Synthesis and calculated properties of some 1,4-bis(amino)anthracene-9,10-diones Org Biomol Chem 4 2006 4005 4014 (Pubitemid 44600673)
19. A.P. Krapcho, M.E. Petry, Z. Getahun, J.J. Landi Jr., J. Stallman, J.F. Polsenberg, C.E. Gallagher, M.J. Maresch, M.P. Hacker, F.C. Giuliani, G. Beggiolin, G. Pezzoni, E. Menta, C. Manzotti, A. Oliva, S. Spinelli, and S. Tognella 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations J Med Chem 37 1994 828 837 (Pubitemid 24123481)
20. P. Canal, M. Attal, E. Chatelut, S. Guichard, F. Huguet, and C. Muller Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas Cancer Res 53 1993 4850 4854 (Pubitemid 23326177)
21. J. Hesselgesser, and R. Horuk Chemokine and chemokine receptor expression in the central nervous system J Neurovirol 5 1999 13 26 (Pubitemid 29051874)
22. A. Liston, R.E. Kohler, S. Townley, S. Haylock-Jacobs, I. Comerford, and A.C. Caon Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response J Immunol 182 2009 3121 3130
23. B.D. Trapp, L. Bö, S. Mörk, and A. Chang Pathogenesis of tissue injury in MS lesions J Neuroimmunol 98 1999 49 56 (Pubitemid 29295407)
24. Y. Komiyama, S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, and S. Kakuta IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis J Immunol 177 2006 566 573 (Pubitemid 43939170)
25. L. Steinman A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage Nat Med 13 2007 139 145
26. J.R. Lees, P.T. Golumbek, J. Sim, D. Dorsey, and J.H. Russell Regional CNS responses to IFN-γ determine lesion localization patterns during EAE pathogenesis J Exp Med 205 2008 2633 2642
27. A.C. Murphy, S.J. Lalor, M.A. Lynch, and K.H.G. Mills Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis Brain Behav Immun 24 2010 641 651
28. D.J. Cua, J. Sherlock, Y. Chen, C.A. Murphy, B. Joyce, and B. Seymour Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 2003 744 748 (Pubitemid 36227625)
29. A.C. Murphy, C.L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, and R.A. Kastelein Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation J Exp Med 198 2003 1951 1957 (Pubitemid 38032126)
30. G.X. Zhang, B. Gran, S. Yu, J. Li, I. Siglienti, and X. Chen Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system J Immunol 170 2003 2153 2160 (Pubitemid 36197439)
31. C.C. Ferrari, A.M. Depino, F. Prada, N. Muraro, S. Campbell, and O. Podhajcer Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain Am J Pathol 165 2004 1827 1837 (Pubitemid 39435180)
32. M. Veldhoen, R.J. Hocking, C.J. Atkins, R.M. Locksley, and B. Stockinger TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells Immunity 24 2006 179 189 (Pubitemid 43214587)